Andrew is a Senior Counsel in the Patents team and offers expert counsel on contentious patent and regulatory matters. Leveraging his previous experience as a medicinal chemist in the pharmaceutical industry, he is particularly focused on advising companies within the life sciences sector.
Declaratory Relief in the English Patents Court, Bio-Science Law Review, 2016, p 123-128
Patents Overhauled: Impact of the America Invents Act on the Pharmaceutical Industry (co-author), European Biopharmaceutical Review, Spring 2015
New and Approved: The New EU Clinical Trials Regulation (co-author), European Pharmaceutical Contractor, December 2014 p 50-53
par plusieurs auteurs
Brexit and beyond – Wellcome's recommendations from the Future Partnership Project
par Andrew Payne
Licence held to be exclusive despite option
par Andrew Payne
par plusieurs auteurs
par Siedse Willems
par Evelyne Friedel et Axel Ferly
par Nicholas Vollers et Adrian Toutoungi
par Charlie Adams et Adrian Toutoungi
par plusieurs auteurs